These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 11910259)

  • 21. A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD).
    Alaghband-Rad J; Hakimshooshtary M
    Eur Child Adolesc Psychiatry; 2009 Mar; 18(3):131-5. PubMed ID: 19190958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
    Riddle MA; Scahill L; King RA; Hardin MT; Anderson GM; Ort SI; Smith JC; Leckman JF; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1062-9. PubMed ID: 1429406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?
    Onder E; Tural U; Gökbakan M
    Eur Arch Psychiatry Clin Neurosci; 2008 Sep; 258(6):319-23. PubMed ID: 18297416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preschool children with obsessive-compulsive disorder and fluoxetine treatment.
    Ercan ES; Kandulu R; Akyol Ardic U
    Eur Child Adolesc Psychiatry; 2012 Mar; 21(3):169-72. PubMed ID: 22271063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.
    Geller DA; Hoog SL; Heiligenstein JH; Ricardi RK; Tamura R; Kluszynski S; Jacobson JG;
    J Am Acad Child Adolesc Psychiatry; 2001 Jul; 40(7):773-9. PubMed ID: 11437015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy assessment of fluoxetine treatment of outpatients with obsessive-compulsive disorder: a preliminary report].
    Wandzel L
    Psychiatr Pol; 1997; 31(4):429-35. PubMed ID: 9527686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.
    Diniz JB; Shavitt RG; Fossaluza V; Koran L; Pereira CA; Miguel EC
    J Clin Psychopharmacol; 2011 Dec; 31(6):763-8. PubMed ID: 22020357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder.
    Greist JH; Jefferson JW; Kobak KA; Chouinard G; DuBoff E; Halaris A; Kim SW; Koran L; Liebowtiz MR; Lydiard B
    Int Clin Psychopharmacol; 1995 Jun; 10(2):57-65. PubMed ID: 7673657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial.
    Belotto-Silva C; Diniz JB; Malavazzi DM; Valério C; Fossaluza V; Borcato S; Seixas AA; Morelli D; Miguel EC; Shavitt RG
    J Anxiety Disord; 2012 Jan; 26(1):25-31. PubMed ID: 21907540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
    Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Serlin RC
    Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M; Bulut SD; Bozkurt A; Ozsahin A
    Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder.
    Sousa MB; Isolan LR; Oliveira RR; Manfro GG; Cordioli AV
    J Clin Psychiatry; 2006 Jul; 67(7):1133-9. PubMed ID: 16889458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluoxetine in acute treatment of children and adolescents with obsessive-compulsive disorder: a systematic review and meta-analysis.
    Maneeton N; Maneeton B; Karawekpanyawong N; Woottiluk P; Putthisri S; Srisurapanon M
    Nord J Psychiatry; 2020 Oct; 74(7):461-469. PubMed ID: 32242450
    [No Abstract]   [Full Text] [Related]  

  • 36. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
    Simpson HB; Gorfinkle KS; Liebowitz MR
    J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Gamel NN
    J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.
    Pediatric OCD Treatment Study (POTS) Team
    JAMA; 2004 Oct; 292(16):1969-76. PubMed ID: 15507582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders.
    Hollander E; Soorya L; Chaplin W; Anagnostou E; Taylor BP; Ferretti CJ; Wasserman S; Swanson E; Settipani C
    Am J Psychiatry; 2012 Mar; 169(3):292-9. PubMed ID: 22193531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
    Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
    J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.